NeuroSigma

Executive Summary

NeuroSigma is a Los Angeles-based bioelectronic medical device company pioneering non-invasive trigeminal nerve stimulation (TNS) for neurological and neuropsychiatric disorders. Its lead product, the Monarch eTNS System, received FDA clearance for pediatric ADHD, offering a drug-free alternative with a favorable safety profile. The growing concerns over stimulant side effects and the need for non-pharmacological options position NeuroSigma to capture a significant share of the ADHD market. The company's technology is also being investigated for epilepsy, depression, and PTSD, broadening its potential addressable market. With a strong intellectual property portfolio and a first-mover advantage in eTNS, NeuroSigma is well-positioned for growth, though commercialization remains early-stage. Financially, NeuroSigma operates as a private company with limited public disclosure. Its valuation and funding history are not disclosed, but the company has likely relied on grants, angel investors, and strategic partnerships. The success of Monarch eTNS hinges on physician adoption, reimbursement coverage, and positive real-world evidence. While the market opportunity is substantial, competition from other neurostimulation modalities and behavioral therapies presents challenges. Near-term catalysts include potential label expansion to adult ADHD, pivotal trial results for epilepsy, and strategic alliances with larger healthcare companies. Overall, NeuroSigma represents a high-risk, high-reward opportunity in the emerging field of bioelectronic medicine.

Upcoming Catalysts (preview)

• Q2 2027FDA clearance expansion to adult ADHD or epilepsy60% success
• Q4 2026Publication of pivotal trial results for major depressive disorder50% success
• Q3 2026Strategic partnership or licensing deal with a larger pharmaceutical or medical device company40% success